Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
Authors:
- Juan J. LahuertaJLJuan J. Lahuerta
- José D. GonzálezJGJosé D. González
- Paz RibasPRPaz Ribas
- Carlos SolanoCSCarlos Solano
- Adrían AlegreAAAdrían Alegre
- Joan BladéJBJoan Bladé
- Jesús F. San MiguelJMJesús F. San Miguel
- Miguel A. SanzMiguel A. Sanz
- Javier de la RubiaJRJavier de la Rubia
Open Access
- 1 January 2013
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 19 (1) , 69-74
Abstract
No abstract availableKeywords
Funding Information
- “Red Temática de Investigación Cooperativa en Cancer” (RD06/0020/0031 and RD06/0020/0005)
- “Red de Biobancos Hospitalarios” (RD09/0076/00021)
- “Instituto de Salud Carlos III” (PS09/01882)
- “Instituto de Salud Carlos III” (CA08/00141, CM10/00321, CM09/00038)
- “Ministerio de Ciencia e Innovacion” (BES2008-008053)
This publication has 37 references indexed in Scilit:
- Current Multiple Myeloma Treatment Strategies with Novel Agents: A European PerspectiveThe Oncologist, 2010
- Autologous transplantation for multiple myelomaAnnals of Oncology, 2008
- High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myelomaLeukemia Research, 2007
- Stem-cell transplantation in multiple myelomaBest Practice & Research Clinical Haematology, 2005
- Five decades of therapy for multiple myeloma: a paradigm for therapeutic modelsLeukemia, 2005
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trialBlood, 2002
- Long-term follow-up after high-dose therapy for high-risk multiple myelomaBone Marrow Transplantation, 1998
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myelomaBritish Journal of Haematology, 1995